In this research article, human adipose-derived mesenchymal progenitor cells were investigated both for safety and efficacy in treating cartilage defects in 30 patients.
The Regenerative Medicine journal has published a new Phase II clinical trial seeking to assess the safety and efficacy of utilizing human mesenchymal stem cells in the repair of cartilage defects in thirty patients. By treating patients with the mesenchymal progenitor cells, commonly understood to be able to undergo differentiation into chondrocytes and osteoblasts, alongside a microfracture and hyaluronic acid approach, the researchers were investigating the ability to relieve joint pain in patients.
Aim: The study aimed to preliminarily evaluate the safety and efficacy of utilizing human adipose-derived mesenchymal progenitor cells, in combination with microfracture and hyaluronic acid, to treat cartilage defects.
Materials & methods: 30 patients with medial femoro-tibial condylar cartilage defects were randomized into three groups: arthroscopic microfracture group and normal saline injection, arthroscopic microfracture and intra-articular injection of hyarluronic acid, or arthroscopic microfracture in combination with intra-articular injection of hyaluronic acid and adipose-derived mesenchymal progenitor cells.
The results are published in the latest issue of Regenerative Medicine.
Have any additional questions about this story? Ask us in the comments, below.
Find out more in these top picks from the Editor:
- Adipose-derived mesenchymal stem cell therapy in the treatment of knee osteoarthritis: a randomized controlled trial
- G-CSF enhances the therapeutic potency of stem cells transplantation in spinal cord-injured rats
- Peek behind the paper: bone healing from organoids